Roquefort Therapeutics PLC
ROQ
Company Profile
Business description
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. The product portfolio of the company consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical development of next-generation medicines focused on hard-to-treat cancers.
Contact
85 Great Portland Street
First Floor
LondonW1W 7LT
GBRT: +44 2039188633
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1
Stocks News & Analysis
stocks
Chart of the Week: Opportunities with wide-moat retailers
Consumer defensive names look undervalued.
stocks
New ASX share added to our best ideas
Earnings outlook is strong and the shares trade at a discount to our fair value.
stocks
Fair value downgraded for ASX heavyweight
Our capital allocation rating was also lowered due to balance sheet weakness.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,240.30 | 42.60 | 0.46% |
| CAC 40 | 8,075.76 | 108.81 | 1.37% |
| DAX 40 | 24,449.08 | 335.46 | 1.39% |
| Dow JONES (US) | 46,441.10 | 43.21 | 0.09% |
| FTSE 100 | 9,453.25 | 6.82 | 0.07% |
| HKSE | 27,287.12 | 431.56 | 1.61% |
| NASDAQ | 22,755.16 | 95.15 | 0.42% |
| Nikkei 225 | 44,936.73 | 385.88 | 0.87% |
| NZX 50 Index | 13,451.76 | 17.77 | 0.13% |
| S&P 500 | 6,711.20 | 22.74 | 0.34% |
| S&P/ASX 200 | 8,945.90 | 40.10 | 0.45% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |